Cipla Limited has announced the superannuation of Dr Raju Mistry, Global Chief People Officer and Senior Management Personnel, effective December 31, 2025. The announcement was made through a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Key Details of the Announcement

The pharmaceutical company submitted the disclosure on December 30, 2025, to multiple stock exchanges where its shares are listed. The filing confirms that Dr Mistry will retire from his position as Global Chief People Officer on the last day of 2025.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. This regulation requires listed companies to inform stock exchanges about material events and information that could impact investor decisions.

Stock Exchange Notifications

Cipla submitted the announcement to three exchanges where its securities are traded:

• BSE Limited: Scrip Code 500087
• National Stock Exchange of India Limited: Scrip Code CIPLA EQ
• Societe de la Bourse de Luxembourg: International listing

The company stated that it will announce Dr Mistry's successor in due course, indicating that the transition planning process is underway. The filing was signed by Rajendra Chopra, Company Secretary, and prepared by Pavankumar Yadav.

About the Position

As Global Chief People Officer, Dr Mistry holds a senior management position responsible for human resources strategy and operations across Cipla's global operations. His superannuation marks the end of his tenure in this key leadership role at the pharmaceutical company.

Cipla Limited , a prominent player in the Indian pharmaceutical industry, has received an updated Environmental, Social, and Governance (ESG) rating of 68 from ESG Risk Assessments & Insights Limited (ESGRisks.ai), a SEBI-registered ESG rating provider. This represents an improvement from the company's previous ESG rating of 60, demonstrating enhanced performance in sustainable and responsible business practices.

Latest Rating Communication

The pharmaceutical major received communication about the updated ESG rating on December 22, 2025, at 13:36 hours IST. In compliance with regulatory requirements, Cipla promptly disclosed this information to multiple stock exchanges including BSE Limited, National Stock Exchange of India Limited, and Societe de la Bourse de Luxembourg.

Independent Assessment Framework

The ESG rating was independently assigned by ESGRisks.ai, underlining the credibility and impartiality of the assessment. This independent evaluation provides stakeholders with an objective view of Cipla's performance across environmental, social, and governance parameters, showing measurable improvement in the company's ESG initiatives.

Regulatory Compliance and Disclosure

The disclosure aligns with the Securities and Exchange Board of India (SEBI) regulations, specifically Regulation 30 read with Schedule III Part A Para B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication also adheres to SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, which pertains to ESG rating disclosures.

Market Implications

For investors and stakeholders, the improved ESG rating of 68 demonstrates Cipla's enhanced commitment to sustainable business practices. ESG ratings are increasingly becoming crucial factors for investors who prioritize companies with strong environmental, social, and governance track records. The rating improvement from 60 to 68 indicates positive momentum in the company's ESG initiatives and may attract ESG-focused investment flows.

The pharmaceutical company's proactive approach in obtaining and disclosing ESG ratings reflects its awareness of evolving market expectations and regulatory requirements in the sustainability space.